By using samples of blood, solid tissue, or urine, the company plans to develop its platform as an assessment tool for DNA adducts. Credit: totojang1977 / Shutterstock. Aditxt subsidiary Pearsanta has acquired patents associated with adductomics-based DNA damage detection, to make significant advancements in cancer diagnostics. Valued at nearly $1m, the acquisition involved the issuance